Contract notice: Pharmaceutical products Tender, Germany - 14864542

Procurement Summary

Country : Germany

Summary : Contract notice: Pharmaceutical products

Deadline : 30 Sep 2019

Other Information

Notice Type : Tender

TOT Ref.No.: 14864542

Document Ref. No. : 273210-2017

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Purchaser : KKH KAUFMÄNNISCHE KRANKENKASSE
Office Name: KKH Kaufmännische Krankenkasse
Address: Karl-Wiechert-Allee 61
Town: Hanover
Postal Code: 30625

Attention: Sven Seißelberg
Phone: +49 5112802-3376
Fax: +49 5112802-3396
Germany
Email :sven.seisselberg@kkh.de
URL :www.kkh.de

Tender Details

Object of the contract
Pharmaceutical products

Description: Contract notice: Pharmaceutical products

Authority Type: Body governed by public law
Contact Nature: Supplies
Procedure: Open procedure
Document: Contract notice
Regulation: European Union
Award criteria: Not specified
CPV code: 33600000, 33600000
CPV Description: Conclusion of non-exclusive discount agreements pursuant to - 130a para. 8 SGB V to Prasugrel (ATC: B01AC22) with the possibility of closing at any time under the so-called open-house procedure, With all appropriate pharmaceutical companies, discount agreements pursuant to - 130a Paragraph 8 SGB V above the above- WIn accordance with - 130a para. 8 SGB V, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies shall be entitled to conclude or join a contract under the terms of an open-house procedure The above active ingredientPharmaceutical companies may be required to do so under the provisions of l.1. And the contract. At the same time as the requirement of the contract documents, the pharmaceutical company shall be required to submit appropriate authorizations for medicinal products with the above-mentioned. Active substance. The detection may e.g. About a corresponding extract of the AMIS-DAtebank. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits and submits the requested participation documents in full and signed. A contract is concluded with every pharmaceutical company that fulfills the prerequisites for participation. An exclusivity is not given. The accession or the contractCan be concluded at any time and under the same conditions. Individual contract negotiations are not carried out.

The earliest start of the contract is 1 October 2017. Should the KKH during the term of the contract for the active substances carry out an invitation to tender for exclusive contracts in the form of the open procedure, the contracts concluded within the scope of this publication will be publishedThe present publication is not a public procurement contract within the meaning of the Public Procurement Direc- tive of Directives. In order to ensure the widest degree of transparency for the intended conclusion of the contract, the supplement is published in the Official Journal of the European CommunitiesEn Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual specifications, such as the procedure name "open procedure", are solely due to the use of this publication form and to the publishing platformUnless otherwise provided for by law, without prejudice to legal requirements.

A contract shall be concluded no later than 10 days after publication of this notice.

Information and formalities necessary for evaluating if the requirements are met:

- Or commercial register extract in copy (at the time of the expiry of the offer period)6 months), - Signature and stamped declaration of authenticity according to the conditions of participation
Internet address (URL): www.kkh.de
Directive: Classical Directive (2004/18/EC)

Documents

 Tender Notice